Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Aug;103(4):1939–1945. doi: 10.1111/j.1476-5381.1991.tb12356.x

Inotropic and electrophysiological effects of BDF 9148, a congener of DPI 201-106, in guinea-pig atria and papillary muscles.

H Brasch 1, H Iven 1
PMCID: PMC1908210  PMID: 1912981

Abstract

1. BDF 9148 is a newly synthesized congener of DPI 201-106 in which the piperazidinyl moiety has been replaced by an azetidine-3-oxy-moiety. The inotropic effect of both drugs was studied as well as their influence on the action potential, by use of standard microelectrode techniques. 2. BDF 9148 increased the contractile force of guinea-pig atria and papillary muscles. The EC50 was 1.32 X 10(-7) mol l-1 and 0.7 X 10(-6) mol l-1 respectively. DPI 201-106 was effective in a similar concentration-range, the EC50 being 2.6 X 10(-7) mol l-1 for atria and 2.8 X 10(-7) mol l-1 for papillary muscles. 3. Both drugs caused a concentration-dependent prolongation of the relaxation time of the isometric contraction curve. With 10(-6) mol l-1 BDF 9148, the mean increase was 39.1 +/- 4.4 ms in atria and 39.4 +/- 7.5 ms in papillary muscles while 10(-6) mol l-1 DPI 201-106 caused increases of 56.7 +/- 2.5 ms and 79.3 +/- 11.7 ms, respectively. The effect of BDF 9148 was not prevented by propranolol, but was reversed by 3 X 10(-6) mol l-1 tetrodotoxin. Pretreatment of atria with 3 X 10(-8) mol l-1 BDF shifted the concentration-response curve of ouabain to the left and reduced the EC50 of the glycoside from 3.21 X 10(-7) mol l-1 to 2 X 10(-7) mol l-1. 4. BDF 9148 and DPI 201-106 concentration-dependently increased the action potential duration of papillary muscles and their functional refractory period. The drugs did not modify the resting potential, the action potential amplitude or the maximum depolarization velocity.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
1939

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bristow M. R., Ginsburg R., Minobe W., Cubicciotti R. S., Sageman W. S., Lurie K., Billingham M. E., Harrison D. C., Stinson E. B. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982 Jul 22;307(4):205–211. doi: 10.1056/NEJM198207223070401. [DOI] [PubMed] [Google Scholar]
  2. Buggisch D., Isenberg G., Ravens U., Scholtysik G. The role of sodium channels in the effects of the cardiotonic compound DPI 201-106 on contractility and membrane potentials in isolated mammalian heart preparations. Eur J Pharmacol. 1985 Dec 3;118(3):303–311. doi: 10.1016/0014-2999(85)90141-4. [DOI] [PubMed] [Google Scholar]
  3. Butrous G. S., Debbas N. M., Erwin J., Davies D. W., Keller H. P., Lunnon M. W., Nathan A. W., Camm A. J. Clinical cardiac electrophysiologic evaluation of the positive inotropic agent, DPI 201-106. Eur Heart J. 1988 May;9(5):489–497. doi: 10.1093/oxfordjournals.eurheartj.a062534. [DOI] [PubMed] [Google Scholar]
  4. Böhm M., Diet F., Feiler G., Kemkes B., Kreuzer E., Weinhold C., Erdmann E. Subsensitivity of the failing human heart to isoprenaline and milrinone is related to beta-adrenoceptor downregulation. J Cardiovasc Pharmacol. 1988 Dec;12(6):726–732. doi: 10.1097/00005344-198812000-00015. [DOI] [PubMed] [Google Scholar]
  5. Feldman M. D., Copelas L., Gwathmey J. K., Phillips P., Warren S. E., Schoen F. J., Grossman W., Morgan J. P. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation. 1987 Feb;75(2):331–339. doi: 10.1161/01.cir.75.2.331. [DOI] [PubMed] [Google Scholar]
  6. Hof R. P., Hof A. Mechanism of the vasodilator effects of the cardiotonic agent DPI 201-106. J Cardiovasc Pharmacol. 1985 Nov-Dec;7(6):1188–1192. doi: 10.1097/00005344-198511000-00028. [DOI] [PubMed] [Google Scholar]
  7. Hogan J. C., Greenbaum R. A., Lunnon M. W., Hilson A. J., Evans T. R. Haemodynamic effects of DPI 201-106, following single intravenous dose administration to patients with moderate cardiac failure. Eur Heart J. 1988 May;9(5):498–502. doi: 10.1093/oxfordjournals.eurheartj.a062535. [DOI] [PubMed] [Google Scholar]
  8. Holck M., Osterrieder W. Interaction of the cardiotonic agent DPI 201-106 with cardiac Ca2+ channels. J Cardiovasc Pharmacol. 1988 Apr;11(4):478–482. doi: 10.1097/00005344-198804000-00015. [DOI] [PubMed] [Google Scholar]
  9. Honerjäger P. Cardioactive substances that prolong the open state of sodium channels. Rev Physiol Biochem Pharmacol. 1982;92:1–74. doi: 10.1007/BFb0030502. [DOI] [PubMed] [Google Scholar]
  10. Honerjäger P., Reiter M. The relation between the effects of veratridine on action potential and contraction in mammalian ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol. 1975;289(1):1–28. doi: 10.1007/BF00498026. [DOI] [PubMed] [Google Scholar]
  11. Kihara Y., Gwathmey J. K., Grossman W., Morgan J. P. Mechanisms of positive inotropic effects and delayed relaxation produced by DPI 201-106 in mammalian working myocardium: effects on intracellular calcium handling. Br J Pharmacol. 1989 Apr;96(4):927–939. doi: 10.1111/j.1476-5381.1989.tb11904.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kohlhardt M., Fröbe U., Herzig J. W. Removal of inactivation and blockade of cardiac Na+ channels by DPI 201-106: different voltage-dependencies of the drug actions. Naunyn Schmiedebergs Arch Pharmacol. 1987 Feb;335(2):183–188. doi: 10.1007/BF00177721. [DOI] [PubMed] [Google Scholar]
  13. Kostis J. B., Lacy C. R., Raia J. J., Dworkin J. H., Warner R. G., Casazza L. A. DPI 201-106 for severe congestive heart failure. Am J Cardiol. 1987 Dec 1;60(16):1334–1339. doi: 10.1016/0002-9149(87)90617-5. [DOI] [PubMed] [Google Scholar]
  14. Rüegg P. C., Nüesch E. The effect of a new inotropic agent, DPI 201-106, on systolic time intervals and the electrocardiogram in healthy subjects. Br J Clin Pharmacol. 1987 Oct;24(4):453–458. doi: 10.1111/j.1365-2125.1987.tb03197.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Scholtysik G., Salzmann R., Berthold R., Herzig J. W., Quast U., Markstein R. DPI 201-106, a novel cardioactive agent. Combination of cAMP-independent positive inotropic, negative chronotropic, action potential prolonging and coronary dilatory properties. Naunyn Schmiedebergs Arch Pharmacol. 1985 May;329(3):316–325. doi: 10.1007/BF00501887. [DOI] [PubMed] [Google Scholar]
  16. Scholtysik G., Salzmann R., Gerber W. Interaction of DPI 201-106 with cardiac glycosides. J Cardiovasc Pharmacol. 1989 Feb;13(2):342–347. doi: 10.1097/00005344-198902000-00026. [DOI] [PubMed] [Google Scholar]
  17. Siegl P. K., Garcia M. L., King V. F., Scott A. L., Morgan G., Kaczorowski G. J. Interactions of DPI 201-106, a novel cardiotonic agent, with cardiac calcium channels. Naunyn Schmiedebergs Arch Pharmacol. 1988 Dec;338(6):684–691. doi: 10.1007/BF00165635. [DOI] [PubMed] [Google Scholar]
  18. Wang G., Dugas M., Ben Armah I., Honerjäger P. Interaction between DPI 201-106 enantiomers at the cardiac sodium channel. Mol Pharmacol. 1990 Jan;37(1):17–24. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES